Trials / Unknown
UnknownNCT01847118
A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (estimated)
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
This study is to assess the safety, tolerability and pharmacokinetics of single dose and multiple doses of humanized anti-VEGF monoclonal antibody (Sevacizumab) in patients with advanced or metastatic solid tumors. The secondary objective is to explore the preliminary anti-tumor effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sevacizumab |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2015-11-01
- Completion
- 2015-11-01
- First posted
- 2013-05-06
- Last updated
- 2015-03-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01847118. Inclusion in this directory is not an endorsement.